NCT00779636 is a Phase 4 clinical trial of Desloratadine in Allergic Airway Disease, sponsored by Organon and Co.

Who is sponsoring NCT00779636?

NCT00779636 is sponsored by Organon and Co.

What drugs are being tested in NCT00779636?

Interventions in NCT00779636: Desloratadine, Placebo.

What condition does NCT00779636 study?

NCT00779636 studies Allergic Airway Disease.

Is NCT00779636 still recruiting?

NCT00779636 is currently completed. Last updated 15 August 2024.

Last reviewed 2024-08-15 · How we verify

NCT00779636

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effectiveness and Safety of Desloratadine in Patients With Allergic Airway Disease During the Pollen Season (Study P03284)

Completed Phase 4 Last updated 15 August 2024

What this trial tests

Phase 4 trial testing Desloratadine in Allergic Airway Disease in 506 participants. Completed in 1 November 2004.

Timeline

1 July 2003

Primary endpoint
1 November 2004

1 November 2004

Quick facts

Lead sponsor	Organon and Co
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	506
Start date	1 July 2003
Primary completion	1 November 2004
Estimated completion	1 November 2004

Drugs / interventions tested

Desloratadine (desloratadine) — full drug profile →
Placebo

Conditions studied

Allergic Airway Disease — all drugs for Allergic Airway Disease →

Sponsor

Organon and Co — full company profile →

Who can join

Adults 18 to 65, any sex, with Allergic Airway Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This was a placebo controlled study designed to evaluate the effectiveness of desloratadine in relieving symptoms of allergic airway disease during the pollen season. Patients received desloratadine 10 mg or placebo once daily for 28 days, and had their allergy symptoms and side effects to medication measured on Day 1, Day 15, and Day 29 (one day after stopping study drug).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Desloratadine

Trials testing the same drug.

NCT07486583 — Autologous Whole Blood Therapy in Chronic Idiopathic Urticaria Patients. · Phase 3 · not yet recruiting
NCT06916884 — Confirmatory Study on the Efficacy and Safety of the Fixed-dose Combination of Desloratadine/Betamethasone Versus Deslor · Phase 3 · recruiting
NCT05214911 — Fixed Dose Combination of Desloratadine / Prednisolone in the Treatment of Moderate Severe Allergic Rhinitis in Children · Phase 3 · completed
NCT06268470 — Antiplatelet Therapy in Chronic Urticaria · Phase 2 · unknown
NCT01916967 — An Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Chronic Urticaria (MK-4117-201) · Phase 3 · completed

Other Organon and Co trials

Trials by the same sponsor.

NCT05761444 — Effectiveness and Safety Study of Early add-on of Ezetimibe With Atorvastatin in Very High-risk Patients · Phase 4 · completed
NCT05789576 — A Study to Investigate Efficacy and Safety of VTAMA® (Tapinarof) Cream, 1% in Plaque Psoriasis in the Head and Neck Regi · Phase 4 · completed
NCT05680740 — A Study to Investigate Efficacy and Safety of VTAMA (Tapinarof) Cream, 1% in Intertriginous Plaque Psoriasis · Phase 4 · completed
NCT05560646 — A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 · Phase 2 · completed
NCT05264506 — Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive · Phase 3 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00779636 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Organon and Co
Last refreshed: 15 August 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00779636.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing